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Vascular calcification is a recognized risk factor for
cardiovascular mortality in patients with end-stage renal
disease. The aim of this study was to identify risk factors for
vascular access calcification and to determine if patients with
this disorder are at increased risk of death. Vascular access
calcification was found in 49 of 212 hemodialysis patients as
measured by plain X-ray (arteriovenous fistula or synthetic
graft) in two dimensions. Male gender, diabetes mellitus, and
length of time on dialysis were independent predictors for
access calcification determined by logistic regression
multivariate analysis. Serum parameters were not
independently related to access calcification. Kaplan–Meier
analysis showed an increased mortality risk, and Cox
regression analysis confirmed that vascular access
calcification was an independent mortality predictor. Our
study suggests that detection of vascular access calcification
is a cost-effective method to identify patients at increased
mortality risk.
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Patients with end-stage renal disease exhibit a dramatically
increased cardiovascular mortality in comparison with the
normal population.1 Vascular calcifications are important
predictors of mortality in end-stage renal disease patients on
hemodialysis.2 Uremia-associated risk factors like chronic
inflammation, hyperphosphatemia, and an increased cal-
cium–phosphate product and deficiencies of calcification
inhibitors contribute to progressive vascular calcification in
end-stage renal disease patients.3–5 Different methods have
been used to detect the influence of vascular calcifications on
mortality risk of dialysis patients.2,6 Nevertheless, easy to
perform single modality methods for the detection of
calcification are limited.
Vascular access calcification (VAC)—calcification of the
arteriovenous fistula or the synthetic graft—can be detected
easily by plain X-ray. However, there is only limited
information on the prevalence of VAC and risk factors for
the development of such calcifications. Moreover, there are
no data indicating whether the presence of VAC is associated
with increased mortality risk. Thus, the main objectives of
this study were first to analyze risk factors associated with
VAC and second to investigate whether VAC predict mortality
in a cohort of hemodialysis patients.
RESULTS
Clinical risk factors for vascular access calcification
Characteristics of the dialysis population are given in Table 1.
Using plain radiographs calcifications of the vascular access
could be detected in 49 of the 212 hemodialysis patients
(23%; Figure 1). Male patients were 3.95-times more likely to
develop VAC. Patients with VAC had been on hemodialysis
treatment 2.3 years longer than patients lacking VAC.
Diabetic patients had a 3.43-fold risk for VAC compared
with nondiabetic patients. Age, hypertension, and body mass
index were not related to the presence of VAC, whereas
smokers had the tendency to develop more VAC (odds ratio
(OR) 1.73). Age of the vascular access and history of vascular
access thrombosis were no relevant risk factors for VAC
(Table 1).
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Biochemical risk factors for VAC
Patients with VAC exhibited a tendency toward higher
phosphate levels in comparison to patients without VAC
(Table 2). Serum cholesterol levels were 11% lower in patients
with VAC as compared with patients without VAC, whereas
triglyceride levels were only slightly lower in the group with
VAC. Intact parathyroid hormone and serum high-sensitivity
C-reactive protein were not significantly altered in patients
with VAC in comparison to patients without VAC (Table 2).
Levels of the calcification inhibition markers like serum
fetuin-A and undercarboxylated matrix Gla protein were not
significantly different in patients with vs patients without
VAC.
In the multivariate analysis (logistic regression), only male
gender (OR 5.08, 95% confidence interval (CI) 2.18–11.86,
P¼ 0.00016), diabetes mellitus (OR 4.57, CI 1.75–11.95,
P¼ 0.0019), and dialysis vintage (OR 1.15, CI 1.06–1.25,
P¼ 0.0012) remained significant predictors for VAC.
Relation of VAC to other calcification sites and cardiovascular
parameters
Patients with calcifications of carotid arteries or heart valves
had a tendency toward VAC (OR 1.94 and 1.67, P¼ 0.10 and
P¼ 0.14, respectively), whereas the presence of iliacal/femoral
calcifications exhibited a significant correlation with VAC
(OR 5.72, Po0.0001). Carotid intima-media thickness
(IMT) and carotid-femoral pulse wave velocity (PWV) were
only slightly higher in patients with VAC compared with
patients without VAC (Table 1).
Influence of VAC on mortality
In the second part of our study, we performed a survival
analysis to determine the relevance of VAC for an increased
mortality risk. Mean cumulative survival of patients with
VAC was 946 days, whereas patients without VAC had a mean
cumulative survival of 1089 days. Kaplan–Meier analysis
showed that the presence of VAC significantly increased the
risk for death (hazard ratio 2.14, 95% CI 1.11–4.12, P¼ 0.023;
Figure 2). When accounting for age, diabetes, dialysis vintage,
Kt/V, and vascular disease, the presence of VAC remained a
significant predictor for mortality as the Cox regression
analysis confirmed that VAC were an important mortality
Table 1 | Characteristics of patients with vs without vascular access calcification
All patients
(n=212)
No VAC
(n=163)
With VAC
(n=49)
Odds
ratio
95% confidence
interval P value
Age (years) 59±11 60±10 58±12 0.99 0.96–1.02 NS
Male/female 114/98 76 (47%)/87 (53%) 38 (78%)/11(22%) 3.95 1.89–8.27 0.0001
Diabetes mellitus 26 (12%) 14 (8.6%) 12 (24%) 3.43 1.46–8.03 0.003
Hypertension 185 (87%) 142 (87%) 43 (88%) 1.06 0.40–2.79 NS
Smoking 63 (30%) 44 (27%) 19 (39%) 1.73 0.88–3.35 NS
Body mass index (kg/m2) 23.4±3.7 23.6±3.7 22.7±3.6 0.93 0.85–1.02 NS
Dialysis vintage (years) 6.71±4.55 6.2±4.0 8.5±5.8 1.11 1.04–1.19 0.0015
Vascular access age (months) 89±134
(median 67)
80±120
(median 66)
112±190
(median 72)
1.00 1.00–1.00 NS
History of vascular access thrombosis 74 (35%) 58 (36%) 16 (33%) 0.91 0.46–1.79 NS
Synthetic graft (PTFE) 11 (5.2%) 8 (4.9%) 3 (6.1%) 1.26 0.32–4.96 NS
Iliacal/femoral calcification 116 (55%) 76 (47%) 40 (83%) 5.72 2.52–12.98 o0.0001
Carotid calcification (n=208) 150 (71%) 108 (66%) 42 (86%) 1.94 0.87–4.32 NS
Cardiac valve calcification (n=202) 88 (42%) 64 (39%) 24 (49%) 1.67 0.85–3.23 NS
IMT (mm) (n=208) 0.83±0.43 0.82±0.37 0.87±0.58 1.28 0.67–2.45 NS
PWV (m/s) (n=184) 9.7±2.1 9.6±2.0 10.3±2.5 1.16 0.98–1.37 NS
IMT, intima–media thickness; NS, not significant; PWV, pulse wave velocity; PTFE, polytetrafluoroethylene; VAC, vascular access calcification.
Given are numbers, percent, or mean±s.d., range, relative risk (odds ratio) and 95% confidence intervals for the presence of VAC (univariate logistic regression).
Figure 1 | Two-dimensional X-ray with calcification of the
vascular access.
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risk factor (Table 3). The hazard ratio of VAC for
cardiovascular mortality was 1.79 (95% CI 0.81–3.97,
P¼ 0.14).
Comparison of VAC with other risk factors for mortality
As VAC represents an important risk factor for mortality, we
compared the crude effects of other risk factors in a
univariate Cox regression analysis (Table 4). In our study,
only age, high-sensitivity C-reactive protein, IMT, and iliacal/
femoral calcification were significant predictors of mortality.
DISCUSSION
In this study, we investigated the prevalence of VACs in
hemodialysis patients and analyzed risk factors associated
with VAC. In addition, we assessed whether VAC were related
to mortality risk.
In our study, about one-fourth (23%) of the patients
tested positively for calcifications of the vascular access. To
our knowledge, there is only one other study reporting on the
prevalence of VAC.7 Toussaint et al. used computed
tomography fistulograms to assess calcification in the aorta,
subclavian, carotid artery, and arteriovenous fistula in 28
patients. They found VAC in four of their patients (14%),
which is within the same range of our study. However, to our
knowledge, VAC has not been investigated systematically in
relation to risk factors so far.
The first major finding of our study is that independent
risk factors for VAC were male gender, diabetes mellitus, and
dialysis vintage. Other clinical and biochemical parameters
like age, calcium, calcium-phosphate product, parathyroid
hormone, or fetuin-A3–5,8 were not related to VAC in our
study, whereas smokers and higher phosphate serum levels
showed a tendency to be related with VAC. What could be the
reason that we only found few risk factors for VAC?
Arteriovenous fistulas differ from arteries as these are mainly
arterialized veins. In the absence of pathological conditions,
such as chronic venous insufficiency, veins usually do not
calcify, but in a different setting, that is, when exposed to
Table 2 | Serum and dialysis parameters and medication of patients with vs without vascular access calcification
All patients
(n=212)
No VAC
(n=163)
With VAC
(n=49)
Odds
ratio
95% confidence
interval P value
Serum parameters
Protein (g/l) 67.2±5.0 66.9±4.8 68.4±5.6 1.06 0.99–113 NS
Calcium (mmol/l) 2.30±0.18 2.30±0.18 2.28±0.18 0.46 0.082–2.61 NS
Phosphate (mmol/l) 1.62±0.42 1.59±0.41 1.71±0.45 2.01 0.94–4.31 NS
Ca  PO4 product (mmol2/l2) 3.74±1.06 3.68±1.04 3.93±1.13 1.24 0.92–1.67 NS
iPTH (pg/ml) 370±458
(median 192)
367±455
(median 194)
381±473
(median 170)
1.00 1.00–1-00 NS
Cholesterol (mmol/l) 5.14±1.18 5.28±1.13 4.67±1.22 0.57 0.40–0.81 0.001
Triglycerides (mmol/l) 2.27±1.23 2.35±1.31 2.01±0.88 0.76 0.55–1.05 NS
High-sensitive C-reactive protein (mg/l) 9.5±17.4
(median 3.34)
8.62±16.2 12.4±20.9 1.01 0.99–1.03 NS
Serum fetuin-A (g/l) 0.55±0.14 0.56±0.14 0.53±0.15 0.24 0.02–2.54 NS
ucMGP (nmol/l) 187±101 190±105 176±88 1.00 1.00–1.00 NS
Dialysis parameters
Dialysis hours per week 12.3±1.4 12.4±1.3 12.1±1.4 0.87 0.69–1.11 NS
Calcium dialysate (mmol/l) 1.60±0.21 1.61±0.20 1.57±0.22 0.46 0.10–2.06 NS
Kt/V 1.28±0.19 1.30±0.16 1.22±0.26 0.11 0.02–0.69 0.017
iPTH, immunoreactive parathyroid hormone; NS, not significant; ucMGP, undercarboxylated matrix Gla protein; VAC, vascular access calcification.
VAC, number, percent, or mean±s.d., range, relative risk (odds ratio), and 95% confidence intervals for the presence of vascular access calcifications (univariate logistic
regression.
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Figure 2 | Kaplan–Meier analysis of patients with vs no
vascular access calcification (hazard ratio 2.14; 95%
confidence interval 1.11–4.12; P¼ 0.023).
Table 3 | Effect of vascular access calcification on total
mortality determined by univariate and multivariate Cox
regression analysis
Vascular access calcification HR 95% CI P
Univariate analysis 2.14 1.11–4.12 0.023
Multivariate analysis 2.15 1.05–4.39 0.036
HR, hazard ratio; 95% CI, 95% confidence interval.
The variables age, diabetes mellitus, dialysis vintage, Kt/V, and presence of vascular
disease at the start of the study were included in the multivariate analysis.
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different hemodynamics with high blood flow, vascular
remodelling occurs.9 According to a recent study, cephalic
veins can develop calcifications before creation of the
vascular access.10 Thus, whether VAC had developed solely
after the surgery remains speculative.
Different types of cardiovascular calcification (i.e., athero-
sclerotic, medial artery, and cardiac valve calcification) are
likely the consequence of distinct yet overlapping patholo-
gical mechanisms.11 What are potential mechanisms leading
to VAC? First, VAC could be a marker of systemic vascular
calcification. In our study, patients with VAC showed
increased iliacal/femoral calcification and a trend toward
more frequent carotid or cardiac valve calcifications. The
high correlation of VAC with iliacal/femoral calcification
suggests that VAC and iliacal/femoral calcification share
common pathogenic mechanisms. Second, VAC could be a
marker of insufficient dialysis as VAC was related to
decreased Kt/V and increased dialysis vintage. Third,
hemodynamic factors in the vascular access such as
turbulences or high flux, which were not assessed in our
study, could have contributed to local calcification. Taken
together, several factors seem be involved in the development
of VAC. Interestingly, a small study investigated the
ultrastructural basis of VAC and found brushite in addition
to hydroxyl apatite as calcium depositions12 whereas others
found only hydroxyl apatite.13 Thus, one may speculate that
the mechanism(s) of calcification may be different in VAC
when compared with other vascular sites; however, further
investigations are clearly warranted.
The second major finding of our study is that the presence
of VAC is an important risk factor for mortality. This result is
well in agreement with previous findings showing vascular
calcification as being a risk factor for death in dialysis
patients.2,6,14 However, the studies of London et al. and
Adragao et al. needed measurement of calcification at
different sites and/or with different scoring methods. In
contrast, the method by X-ray of the vascular access has the
advantage of being less time and cost consuming. Our
measurement of calcification can easily be applied in dialysis
patients by using a standard clinical procedure (i.e., X-ray).
Especially, those patients who do not have easy access to a
cardiac spiral computed tomography or where technical
issues prevent its application (e.g., those with atrial fibrilla-
tion or massive obesity) can be assessed concerning their
cardiovascular profile and risk. Moreover, this rather simple
method provides a cost-effective measure of calcification and
thus could become a standard screening method for vascular
calcification in hemodialysis patients with a vascular access
including arteriovenous fistulas or synthetic grafts. In clinical
practice, ultrasound can probably be used to detect VAC with
a similar sensitivity as an X-ray examination. In this context,
it is important to note that a recent study comparing a simple
calcification score with the more sensitive assessment of
coronary calcifications by spiral computed tomography
found a very good correlation between these two assess-
ments.15
There are several limitations of our study. The cross-
sectional character of our study, assessing most serum
parameters at only one single time point, decreases the
potential predictive power of individual serum parameters.
This is, why, at least in the case of rapidly fluctuating
parameters such as phosphate and calcium, we used time-
averaged values for the analyses. Another limitation of our
study is that we did not perform flow measurements of the
vascular access as at the start of the study there was no
Doppler ultrasound available. Finally, the radiographic
method to detect calcifications was a simple X-ray technique,
thus, we might have missed early stages of calcification,
which are already present in the form of microcalcifications.
These might be detected by a computed tomography scan but
are too small to be visualized by plain X-ray films. Again,
widespread applicability, ease of performing the method and
cost were our main motivations to omit such more
sophisticated approaches.
In conclusion, we report for the first time a systematic
analysis of predictors and consequences of VAC in hemodia-
lysis patients. The detection of VAC represents a cost-effective
and easy to perform method to identify patients at increased
mortality risk.
MATERIALS AND METHODS
Patients
We prospectively analyzed 212 hemodialysis patients (i.e., all
patients with a vascular access like arteriovenous fistula or synthetic
graft) from the Zvezdara University Medical Centre, Belgrade, Serbia
(Table 1). All chronic hemodialysis patients were eligible to enter the
study if they agreed to participate and had a two-dimensional X-ray
of the vascular access. The vascular access was mainly located on the
distal part of the upper extremity (76%) whereas 24% were
proximally located. Synthetic grafts (polytetrafluoroethylene) were
used in 11 patients (5%). Patients were enrolled between December
Table 4 | Crude effect of vascular access calcification and
clinical, biochemical, and cardiovascular parameters and
other calcification sites on total mortality determined by
univariate Cox regression analysis
Parameter HR 95% CI P
Age (years) 1.04 1.01–1.08 0.007
Dialysis vintage (years) 0.99 0.93–1.06 0.824
Hypertension 1.01 0.42–2.41 0.980
Diabetes mellitus 1.48 0.62–3.53 0.380
BMI (kg/m2) 0.94 0.86–1.03 0.208
Serum calcium (mmol/l) 0.83 0.16–4.40 0.829
Serum phosphate (mmol/l) 0.66 0.31–1.41 0.281
Protein (g/l) 1.00 0.94–1.07 0.927
Hemoglobin (g/dl) 0.89 0.73–1.09 0.267
High sensitive C-reactive protein (mg/l) 1.03 1.02–1.04 o0.001
Pulse wave velocity (m/s) (n=184) 1.19 0.98–1.44 0.084
Carotid IMT (mm) (n=208) 1.83 1.21–2.78 0.004
Iliacal calcification 2.03 1.03–4.00 0.042
Cardiac valve calcification (n=202) 1.80 0.88–3.65 0.106
Carotid calcification (n=208) 1.99 0.87–4.57 0.103
BMI, body mass index; HR, hazard ratio; IMT, intima–media thickness; 95% CI, 95%
confidence interval.
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2003 and October 2005 and observed for 4–40 months until May
2007 (mean follow-up 692 days). During that observation period, 39
deaths occurred (cardiovascular, 28; malignancy, 6; sepsis, 4; ileus,
1). Gender was equally distributed (114 male gender, 98 female
gender). Etiologies for end-stage renal disease were hypertensive
nephrosclerosis, 115 (54%); glomerulonephritis, 26 (12%); auto-
somal-dominant polycystic kidney disease, 21 (10%); pyelonephri-
tis, tubulointerstitial disease and obstructive nephropathy, 25 (12%);
diabetic nephropathy, 12 (6%); systemic lupus erythematosus, 5
(2%); and Balkan endemic nephropathy, 8 (4%). The following
phosphate binders and vitamin D medications were given: calcium
carbonate, 159 (75%); aluminum hydroxide, 21 (10%); calcium
carbonateþ aluminium hydroxide, 24 (11%); no phosphate binder,
8 (4%); 1,25-OH-vitamin D3, 146 (69%); 1-a-OH-vitamin D3, 14
(6.6%); warfarin, 5 (2.4%); calcium antagonists, 89 (42%). The
presence of vascular disease was defined as a preexisting diagnosis of
coronary artery disease, cerebrovascular disease, or peripheral artery
disease. The study protocol was approved by the Ethics Committee
of the Zvezdara University Medical Centre, Belgrade, Serbia, and
each patient gave informed consent.
Vascular access calcification and cardiovascular parameters
Calcification of the vascular access was assessed by plain two-
dimensional X-ray of the arm with arteriovenous fistula or synthetic
graft. X-ray images were analyzed by two experienced physicians
blinded to the patient’s condition. Only clearly visible extraosseous
calcifications were counted as VAC. In addition, calcification of the
iliacal/femoral arteries was determined on plain pelvic X-rays, which
were analyzed by two experienced physicians.
Echocardiography was performed by one experienced investi-
gator to detect calcifications of the aortic and mitral heart valves
using an Aspen-Acuson device (Mountain View, CA, USA). To
determine the intraobserver variability of echocardiographic detec-
tion of valvular calcification, one experienced investigator examined
30 randomly selected patients twice within 14 days. Intraobserver
variability was 4%.
IMT was measured on both carotid arteries by performing a B-
mode ultrasonography of the carotid arteries using an ALOCA SSD
2000 (Tokyo, Japan) system equipment with 7.5 MHz linear
transducers. A trained investigator scanned both common carotid
arteries, 4 cm from the bulbs, the carotid bulbs, and the first 2 cm of
the internal and external carotid arteries. IMT was measured by one
experienced investigator as the distance between adventitia and the
lining of the arterial lumen/intima in a plaque-free area.16,17 It was
measured four times on both sides of the posterior wall (0.5, 1, 2,
and 3 cm below the bifurcation) and the mean of these measure-
ments was recorded. Calcified carotid plaques were defined as
echogenic structures showing protrusion into the lumen with focal
widening that was 50% greater than the IMT of adjacent sites. To
determine the intraobserver variability of IMT measurements, one
experienced investigator examined 30 randomly selected patients
twice within 14 days. Intraobserver variability was 8%.
A Complior SP system (Artech Medical, Pantin, France) was used
to assess the PWV by two trained investigators. PWV was measured
utilizing two sensors (one carotid, one femoral) simultaneously to
determine the velocity of the pulse in relation to the distance
between the femoral artery and the suprasternal notch. Two
measurements were performed and the mean value calculated. To
determine the interobserver variability of PWV measurements, two
experienced investigators independently analyzed 20 randomly
selected patients. Interobserver variability was 7%.
The measurements of carotid calcification detection (n¼ 208),
carotid IMT (n¼ 208), cardiac valve calcification detection
(n¼ 202), and PWV (n¼ 184) were performed during the first
months of the study; failure to perform the measurements in the
remaining patients was mostly due to prior death of the patient.
Biochemistry
Blood was drawn from the arterial site after a long dialysis interval
just before dialysis commenced. Biochemical analysis of serum risk
factors (calcium, phosphate, lipids, protein, cholesterol, and
triglycerides) was performed by standard laboratory procedure
using an automated analyzer. Intact parathyroid hormone was
assessed by a chemiluminescence assay (Diagnostic Product
Corporation, Los Angeles, CA, USA). Serum analysis for high-
sensitivity C-reactive protein was performed by particle-enhanced
immunonephelometry using a standard ‘CardioPhase hsCRP’ for
‘BNII’ (Dade Behring Holding GmbH, Liederbach, Germany). The
nephelometric method for association of serum fetuin-A serum was
adopted from a serum ELISA method as previously described.18 The
ELISA measurement of undercarboxylated matrix Gla protein was
conducted as previously described.19 Calcium and phosphate
measurements were calculated as mean values from four measure-
ments within 4 months before the start of the study. All other
parameters were single measurements at the beginning of the study.
Statistical analysis
Continuous variables were summarized by means and correspond-
ing standard deviations. Comparisons of the values of continuous
variables between two groups were made using an unpaired t-test.
Categorical variables were summarized by relative frequencies. w2-
Test was used for investigating associations between various
categorical variables. Relative risk (odds ratio) and 95% CI for
numerous variables were calculated by univariate logistic regression.
Multivariate statistical analysis (logistic regression, enter method)
was used to account for possible confounders (age, diabetes mellitus,
dialysis vintage, hypertension, body mass index, serum levels of
calcium, phosphate, iPTH, fetuin-A, undercarboxylated matrix Gla
protein, triglyerides, and cholesterol). Cumulative survival was
estimated using the Kaplan–Meier method. To identify prognostic
factors of death, comparisons between survival curves were made by
log-rank test. Cox regression was used (enter method) to determine
the effect of AV-calicifications adjusted for variables (age, diabetes
mellitus, dialysis vintage, Kt/V, and presence of vascular disease at
the beginning of the study). Statistical analysis was performed with
SPSS 14.0. A P-value of o0.05 was considered to be statistically
significant.
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